Bionano Genomics (BNGO) Cash & Equivalents (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Cash & Equivalents data on file, last reported at $3.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 5.52% year-over-year to $3.4 million; the trailing twelve-month figure through Mar 2026 stood at $3.4 million (down 5.52% YoY), and the FY2025 full-year result was $3.0 million, down 67.4% from the prior year.
• Cash & Equivalents grew to $3.4 million in Q1 2026, from $3.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $34.6 million in Q3 2023 to a low of $3.0 million in Q4 2025.
• A 5-year average of $12.8 million and a median of $9.2 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents sank 93.36% in 2022 and soared 283.99% in 2024, its largest moves.
• Tracing BNGO's Cash & Equivalents over 5 years: stood at $5.1 million in 2022, then soared by 252.54% to $17.9 million in 2023, then slumped by 48.89% to $9.2 million in 2024, then tumbled by 67.4% to $3.0 million in 2025, then increased by 14.55% to $3.4 million in 2026.
• Business Quant data shows BNGO's Cash & Equivalents at $3.4 million in Q1 2026, $3.0 million in Q4 2025, and $3.1 million in Q3 2025.